** WARNING, Not error free yet, under construction: check result to a standard work. **

Zuclopenthixol LA

From MedicaWiki
Revision as of 19:43, 23 November 2013 by Walter (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to: navigation, search
zuclopenthixol
long acting
Type antipsychotic
Group classic antipsychotics
links
ATC-code N05AF05
CAS-number 53772-83-1
PubChem 5311507
PubMed zuclopenthixol
drugbank DB01624
Kompas (nl) zuclopenthixol
Wikipedia zuclopenthixol
more info
DDD 15mg [1]
EQ-dosage 0.2[2] haloperidol
T1/2 456h [3]
metabolites 1[4]
bioavailability 40%[3]
administration IM
Price/day 1 [5]

zuclopenthixol (long acting) is an antipsychotic in the group classic antipsychotics.


Caution area Value Ref Description
Lactation 8 [3] Unsafe and possibly harming
Pregnancy 6 [4] high risk - C - suspected to cause reversible damage, but no malfunctions
Diabetes mellitus 4 [6] weak influence on diabetes - safe, monitoring recommended
Hepatic insufficiency 3 [7] Generally safe, unsafe with severe hepatic impairment (Child Pugh classification C - monitoring required)
Children 8 [8] inapplicable - not registered, poorly studied
Elderly 6 [3] average safety - adapt dosage
Dementia 10 [8] not approved for patients with dementia
Chronic Obstructive Pulmonary Disease 2 [9] safe - no adaptation needed, if well-monitored
Hypertension 1 [10] safe - occurrence extremely rare (case-report)
Hypotension 6 [8][3] uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%)
Heart failure 8 [10] strong influence on HF - rather unsafe, continue only if absolutely necessary
Long QT-syndrome 5 [8][11] Conditional risk of QT prolongation and/or TdP* - Arizona Scale - not listed
Seizures 3 [3] rare (between 1 in 1,000 and 1 in 10,000 patients: 0,01% - 0,1%)
Cerebrovascular accidents 8 [10][8] strong influence on CVA - only applicable with frequent monitoring
Renal insufficiency 2 [12] generally safe - unsafe when MDRD < 10 (end stage renal disease (ESRD))
Dyskinesia 8 [3] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Movement disorders 10 [3][8] very common (over 1 in 10 patients: > 10%)
Haematology 6 [3] uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%)
Anticholinergic effects 3 [3] rare (between 1 in 1,000 and 1 in 10,000 patients: 0,01% - 0,1%)
Male sexual dysfunction 10 [10] very common (over 1 in 10 patients: > 10%)
Female sexual dysfunction 10 [10] very common (over 1 in 10 patients: > 10%)
Traffic 6 [4] medium influence (category II) 0,5-0,8 g/l (0,5–0,8‰)
Weight 8 [3] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Weight gain 2 [3][8][4] this drug offers both weight gain and weight loss
Weight loss 2 [3][8][4] this drug offers both weight gain and weight loss
Photosensitivity 7 [13][4] There is a potential risk for photosensitivity reactions
Sedation 8 [8] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Poor CYP2D6 metabolizer 7 [14] (Predominantly)metabolized by this enzyme – monitoring is recommended
Ultra rapid CYP2D6 metabolizer 7 [14] (Predominantly)metabolized by this enzyme – monitoring is recommended
Poor CYPC19 metabolizer 1 [14] No substrate of this enzyme – safe
Ultra rapid CYP2C19 metabolizer 1 [14] No substrate of this enzyme – safe


  1. WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AF05
  2. Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 CVZ; Farmacotherapeutisch Kompas - zuclopentixol (dutch)
  4. 4.0 4.1 4.2 4.3 4.4 4.5 KNMP; Informatorium Medicamentorum 2009; Monografie "zuclopentixol" (Dutch)
  5. parenteraal 20,00/maand/DDD cf FTK: results in €0.67
  6. Lipscombe LL, Lévesque L, Gruneir A et al Antipsychotic Drugs and Hyperglycemia in Older Patients With Diabetes Arch Intern Med 2009;169:1282-1289
  7. Bazire S. Psychotropic drug directory 2007. Trowbridge: Cromwell Press; 2007
  8. 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 Lundbeck Limited; SPC Clopixol® Injection, Clopixol® Conc Injection
  9. Trifirò G, Gambassi G, Sen EF, Caputi AP, Brea J, Sturkenboom MC; Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study; Ann Intern Med 2010;152(7):418-25  (pubmed-id 20368647)
  10. 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 KNMP; Informatorium Medicamentorum 2009; Inleidende tekst "Klassieke Antipsychotica" (Dutch)
  11. van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton-Cheh C, Witteman JC, Stricker BH. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009 Feb;29(1):9-15  (pubmed-id 19142100)
  12. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines, 10th edition. London: Informa Healthcare; 2009
  13. UptoDate - zuclopenthixol
  14. 14.0 14.1 14.2 14.3 Roo, M. de; CYP2D6 and CYP2C19 scores.